At the time of writing, Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $3.46, up 0.87%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AMLX shares have lost -2.26% over the last week, with a monthly amount drifted -10.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on April 07, 2025, when Mizuho upgraded its rating to a Outperform but kept the price target unchanged to $7 for it. Previously, Robert W. Baird upgraded its rating to Outperform on November 18, 2024, and elevated its price target to $11. On October 23, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on March 18, 2024. Robert W. Baird downgraded its rating to a Neutral and reduced its price target to $4 on March 11, 2024. Leerink Partners downgraded its rating to Market Perform for this stock on March 11, 2024, and downed its price target to $4. In a note dated March 08, 2024, Goldman downgraded an Neutral rating on this stock.
For the past year, the stock price of Amylyx Pharmaceuticals Inc fluctuated between $1.58 and $7.27. Currently, Wall Street analysts expect the stock to reach $8.25 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $3.46 at the most recent close of the market. An investor can expect a potential return of 138.44% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
According to Amylyx Pharmaceuticals Inc [NASDAQ:AMLX], the company’s sales were 87.37M for trailing twelve months, which represents an -100.61% plunge. Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -3.34%, Pretax Profit Margin comes in at -3.46%, and Net Profit Margin reading is -3.45%. To continue investigating profitability, this company’s Return on Assets is posted at -1.56, Equity is -1.27 and Total Capital is -1.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.22 points at the first support level, and at 2.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.65, and for the 2nd resistance point, it is at 3.84.
Ratios To Look Out For
It is important to note that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] has a current ratio of 6.67. Also, the Quick Ratio is 6.67, while the Cash Ratio stands at 2.72. Considering the valuation of this stock, the price to sales ratio is 3.51, the price to book ratio is 1.44.
Transactions by insiders
Recent insider trading involved FRATES JAMES M, Chief Financial Officer, that happened on Mar 31 ’25 when 10896.0 shares were sold. Chief Medical Officer, Bedrosian Camille L completed a deal on Mar 31 ’25 to sell 12425.0 shares. Meanwhile, Chief Legal Officer Mazzariello Gina sold 9192.0 shares on Mar 31 ’25.
